JP2004537282A

JP2004537282A - 脳腫瘍の処置及び可視化における生体分子標的の使用法

脳腫瘍の処置及び可視化における生体分子標的の使用法 Download PDF

Info

Publication number: JP2004537282A
Authority: JP; Japan
Prior art keywords: protein; gene; cells; brain; cell
Prior art date: 2001-03-23
Legal status : Pending

Application number

JP2002575022A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004537282A5 (https=

Inventor

サビンムエラー

トールステンメルチャー

ダニエルジェイ．チン

Original Assignee

エージーワイセラピューティクス

Priority date

2001-03-23

Filing date

2002-03-22

Publication date

2004-12-16

2001-03-23 Priority claimed from US09/816,703 external-priority patent/US6455026B1/en

2001-10-17 Priority claimed from US09/983,000 external-priority patent/US20030118585A1/en

2002-03-22 Application filed by エージーワイセラピューティクス filed Critical エージーワイセラピューティクス

2004-12-16 Publication of JP2004537282A publication Critical patent/JP2004537282A/ja

2005-12-22 Publication of JP2004537282A5 publication Critical patent/JP2004537282A5/ja

Status Pending legal-status Critical Current

Links

208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 56
238000011282 treatment Methods 0.000 title claims abstract description 22
238000012800 visualization Methods 0.000 title description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 205
238000000034 method Methods 0.000 claims abstract description 143
102000004169 proteins and genes Human genes 0.000 claims abstract description 105
150000001875 compounds Chemical class 0.000 claims abstract description 42
239000003795 chemical substances by application Substances 0.000 claims abstract description 28
108020004999 messenger RNA Proteins 0.000 claims abstract description 24
101710097877 Brain tumor protein Proteins 0.000 claims abstract description 20
210000004027 cell Anatomy 0.000 claims description 144
230000014509 gene expression Effects 0.000 claims description 84
108090000765 processed proteins & peptides Proteins 0.000 claims description 68
102000004196 processed proteins & peptides Human genes 0.000 claims description 62
150000007523 nucleic acids Chemical class 0.000 claims description 58
102000039446 nucleic acids Human genes 0.000 claims description 54
108020004707 nucleic acids Proteins 0.000 claims description 54
229920001184 polypeptide Polymers 0.000 claims description 52
238000003384 imaging method Methods 0.000 claims description 49
230000000694 effects Effects 0.000 claims description 34
208000005017 glioblastoma Diseases 0.000 claims description 34
206010003571 Astrocytoma Diseases 0.000 claims description 27
231100000433 cytotoxic Toxicity 0.000 claims description 23
230000001472 cytotoxic effect Effects 0.000 claims description 23
210000004881 tumor cell Anatomy 0.000 claims description 21
108700012359 toxins Proteins 0.000 claims description 11
231100000196 chemotoxic Toxicity 0.000 claims description 8
230000002604 chemotoxic effect Effects 0.000 claims description 8
238000007913 intrathecal administration Methods 0.000 claims description 7
108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
230000007423 decrease Effects 0.000 claims description 5
230000003827 upregulation Effects 0.000 claims description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
230000002285 radioactive effect Effects 0.000 claims description 4
239000012905 visible particle Substances 0.000 claims description 4
239000013543 active substance Substances 0.000 claims 3
239000012867 bioactive agent Substances 0.000 claims 1
230000003828 downregulation Effects 0.000 claims 1
238000011820 transgenic animal model Methods 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 49
239000003153 chemical reaction reagent Substances 0.000 abstract description 18
210000005013 brain tissue Anatomy 0.000 abstract description 7
208000030266 primary brain neoplasm Diseases 0.000 abstract description 7
108020004711 Nucleic Acid Probes Proteins 0.000 abstract description 2
239000002853 nucleic acid probe Substances 0.000 abstract description 2
230000001024 immunotherapeutic effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 90
206010028980 Neoplasm Diseases 0.000 description 80
235000001014 amino acid Nutrition 0.000 description 57
230000027455 binding Effects 0.000 description 56
150000001413 amino acids Chemical class 0.000 description 54
230000001225 therapeutic effect Effects 0.000 description 47
239000000523 sample Substances 0.000 description 45
210000004556 brain Anatomy 0.000 description 37
108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
108010029485 Protein Isoforms Proteins 0.000 description 32
102000001708 Protein Isoforms Human genes 0.000 description 32
239000003814 drug Substances 0.000 description 29
238000003556 assay Methods 0.000 description 28
239000000047 product Substances 0.000 description 27
239000002299 complementary DNA Substances 0.000 description 25
239000012634 fragment Substances 0.000 description 25
210000001519 tissue Anatomy 0.000 description 25
125000003729 nucleotide group Chemical group 0.000 description 23
238000012216 screening Methods 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
241001465754 Metazoa Species 0.000 description 22
230000006870 function Effects 0.000 description 20
230000009870 specific binding Effects 0.000 description 20
239000002773 nucleotide Substances 0.000 description 19
125000005647 linker group Chemical group 0.000 description 18
102000005962 receptors Human genes 0.000 description 18
108020003175 receptors Proteins 0.000 description 18
102000040650 (ribonucleotides)n+m Human genes 0.000 description 17
108060003951 Immunoglobulin Proteins 0.000 description 17
229940079593 drug Drugs 0.000 description 17
102000018358 immunoglobulin Human genes 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 17
108700024394 Exon Proteins 0.000 description 16
230000000692 anti-sense effect Effects 0.000 description 16
238000001514 detection method Methods 0.000 description 16
238000012360 testing method Methods 0.000 description 16
230000003321 amplification Effects 0.000 description 15
238000009396 hybridization Methods 0.000 description 15
238000003199 nucleic acid amplification method Methods 0.000 description 15
229940088598 enzyme Drugs 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
239000000975 dye Substances 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
210000002569 neuron Anatomy 0.000 description 13
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
239000000126 substance Substances 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
230000008499 blood brain barrier function Effects 0.000 description 11
210000001218 blood-brain barrier Anatomy 0.000 description 11
201000010099 disease Diseases 0.000 description 11
239000000243 solution Substances 0.000 description 11
108091026890 Coding region Proteins 0.000 description 10
201000010915 Glioblastoma multiforme Diseases 0.000 description 10
108091034117 Oligonucleotide Proteins 0.000 description 10
-1 amplified Chemical class 0.000 description 10
238000013459 approach Methods 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
239000012528 membrane Substances 0.000 description 10
210000004379 membrane Anatomy 0.000 description 10
230000015556 catabolic process Effects 0.000 description 9
238000004113 cell culture Methods 0.000 description 9
239000000562 conjugate Substances 0.000 description 9
230000000875 corresponding effect Effects 0.000 description 9
238000006731 degradation reaction Methods 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
229940072221 immunoglobulins Drugs 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
239000000758 substrate Substances 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 8
206010018338 Glioma Diseases 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000003491 array Methods 0.000 description 8
230000008859 change Effects 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
239000012216 imaging agent Substances 0.000 description 8
230000028993 immune response Effects 0.000 description 8
229940127121 immunoconjugate Drugs 0.000 description 8
230000003993 interaction Effects 0.000 description 8
206010027191 meningioma Diseases 0.000 description 8
238000012545 processing Methods 0.000 description 8
230000014616 translation Effects 0.000 description 8
108010044213 Class 5 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 7
238000010240 RT-PCR analysis Methods 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
238000007792 addition Methods 0.000 description 7
239000000969 carrier Substances 0.000 description 7
239000002975 chemoattractant Substances 0.000 description 7
230000013595 glycosylation Effects 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
239000003446 ligand Substances 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
230000008569 process Effects 0.000 description 7
230000005855 radiation Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
239000013589 supplement Substances 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
230000001988 toxicity Effects 0.000 description 7
231100000419 toxicity Toxicity 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
108020004705 Codon Proteins 0.000 description 6
108010052285 Membrane Proteins Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
229960002685 biotin Drugs 0.000 description 6
235000020958 biotin Nutrition 0.000 description 6
239000011616 biotin Substances 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
229910052740 iodine Inorganic materials 0.000 description 6
239000011630 iodine Substances 0.000 description 6
239000002502 liposome Substances 0.000 description 6
238000002595 magnetic resonance imaging Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000037361 pathway Effects 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
239000003053 toxin Substances 0.000 description 6
231100000765 toxin Toxicity 0.000 description 6
239000013598 vector Substances 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
238000007794 visualization technique Methods 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
102100032312 Brevican core protein Human genes 0.000 description 5
108090000209 Carbonic anhydrases Proteins 0.000 description 5
102000003846 Carbonic anhydrases Human genes 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
108700026244 Open Reading Frames Proteins 0.000 description 5
102100028508 Receptor-type tyrosine-protein phosphatase zeta Human genes 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
102000043977 Tetraspanins Human genes 0.000 description 5
108700031126 Tetraspanins Proteins 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
238000007917 intracranial administration Methods 0.000 description 5
238000002372 labelling Methods 0.000 description 5
150000002611 lead compounds Chemical class 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000002245 particle Substances 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000013519 translation Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108090001008 Avidin Proteins 0.000 description 4
208000036632 Brain mass Diseases 0.000 description 4
101710140080 Brevican core protein Proteins 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
208000006050 Hemangiopericytoma Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
108091092195 Intron Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102100040557 Osteopontin Human genes 0.000 description 4
102100039277 Pleiotrophin Human genes 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
208000026911 Tuberous sclerosis complex Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
210000001130 astrocyte Anatomy 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
239000010839 body fluid Substances 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
230000012010 growth Effects 0.000 description 4
229920002674 hyaluronan Polymers 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
210000004248 oligodendroglia Anatomy 0.000 description 4
239000013610 patient sample Substances 0.000 description 4
102000005162 pleiotrophin Human genes 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
238000002601 radiography Methods 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000012679 serum free medium Substances 0.000 description 4
210000003625 skull Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
241000894007 species Species 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
208000009999 tuberous sclerosis Diseases 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
206010011732 Cyst Diseases 0.000 description 3
208000021994 Diffuse astrocytoma Diseases 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
206010014967 Ependymoma Diseases 0.000 description 3
102000008946 Fibrinogen Human genes 0.000 description 3
108010049003 Fibrinogen Proteins 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
201000010133 Oligodendroglioma Diseases 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
101000714771 Persea americana Cytochrome P450 71A1 Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
239000004365 Protease Substances 0.000 description 3
108091030071 RNAI Proteins 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 3
101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
239000000074 antisense oligonucleotide Substances 0.000 description 3
238000012230 antisense oligonucleotides Methods 0.000 description 3
150000001720 carbohydrates Chemical group 0.000 description 3
230000021164 cell adhesion Effects 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000012292 cell migration Effects 0.000 description 3
210000001638 cerebellum Anatomy 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
208000031513 cyst Diseases 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000035784 germination Effects 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
235000014304 histidine Nutrition 0.000 description 3
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
238000011503 in vivo imaging Methods 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
229930014626 natural product Natural products 0.000 description 3
210000005170 neoplastic cell Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
230000001323 posttranslational effect Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000004952 protein activity Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000002271 resection Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
108010066676 Abrin Proteins 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
206010065869 Astrocytoma, low grade Diseases 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000006452 Class 5 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108060003955 Contactin Proteins 0.000 description 2
102000018361 Contactin Human genes 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
102000016607 Diphtheria Toxin Human genes 0.000 description 2
108010053187 Diphtheria Toxin Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
208000006001 Hypothalamic Neoplasms Diseases 0.000 description 2
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102000002297 Laminin Receptors Human genes 0.000 description 2
108010000851 Laminin Receptors Proteins 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
108091027974 Mature messenger RNA Proteins 0.000 description 2
208000000172 Medulloblastoma Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
102000007000 Tenascin Human genes 0.000 description 2
108010008125 Tenascin Proteins 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
208000014070 Vestibular schwannoma Diseases 0.000 description 2
239000002253 acid Chemical group 0.000 description 2
208000004064 acoustic neuroma Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
229910052789 astatine Inorganic materials 0.000 description 2
RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
108010049223 bryodin Proteins 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000003850 cellular structure Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
201000001169 fibrillary astrocytoma Diseases 0.000 description 2
230000003352 fibrogenic effect Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000030279 gene silencing Effects 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000036541 health Effects 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
201000002222 hemangioblastoma Diseases 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
208000029824 high grade glioma Diseases 0.000 description 2
229940099552 hyaluronan Drugs 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000010874 in vitro model Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
208000030150 low grade astrocytic tumor Diseases 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
239000006166 lysate Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
201000011614 malignant glioma Diseases 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
210000000274 microglia Anatomy 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
238000010232 migration assay Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
231100000862 numbness Toxicity 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000008447 perception Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000002603 single-photon emission computed tomography Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
238000001429 visible spectrum Methods 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
PZINFSHCXYXHOY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-iodopyridine-3-carboxylate Chemical compound IC1=CN=CC(C(=O)ON2C(CCC2=O)=O)=C1 PZINFSHCXYXHOY-UHFFFAOYSA-N 0.000 description 1
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
WKGZJBVXZWCZQC-UHFFFAOYSA-N 1-(1-benzyltriazol-4-yl)-n,n-bis[(1-benzyltriazol-4-yl)methyl]methanamine Chemical compound C=1N(CC=2C=CC=CC=2)N=NC=1CN(CC=1N=NN(CC=2C=CC=CC=2)C=1)CC(N=N1)=CN1CC1=CC=CC=C1 WKGZJBVXZWCZQC-UHFFFAOYSA-N 0.000 description 1
HFJMJLXCBVKXNY-IVZWLZJFSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HFJMJLXCBVKXNY-IVZWLZJFSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
JCTJISIFGZHOFY-UHFFFAOYSA-N 2-(4,6-dichloro-2-methyl-1h-indol-3-yl)ethanamine Chemical compound ClC1=CC(Cl)=C2C(CCN)=C(C)NC2=C1 JCTJISIFGZHOFY-UHFFFAOYSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
KEYRTRGLKSAGJN-UHFFFAOYSA-N 2-iodopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1I KEYRTRGLKSAGJN-UHFFFAOYSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
KVBWBCRPWVKFQT-KPKJHWAZSA-N 3-iodanylbenzoic acid Chemical compound OC(=O)C1=CC=CC([131I])=C1 KVBWBCRPWVKFQT-KPKJHWAZSA-N 0.000 description 1
ZRFXOICDDKDRNA-IVZWLZJFSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 ZRFXOICDDKDRNA-IVZWLZJFSA-N 0.000 description 1
CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical group O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000004373 Actin-related protein 2 Human genes 0.000 description 1
108090000963 Actin-related protein 2 Proteins 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
102000006501 Angiopoietin-like Proteins Human genes 0.000 description 1
108010019425 Angiopoietin-like Proteins Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000006373 Bell palsy Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010039206 Biotinidase Proteins 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
108010085074 Brevican Proteins 0.000 description 1
102000002086 C-type lectin-like Human genes 0.000 description 1
108050009406 C-type lectin-like Proteins 0.000 description 1
102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010033547 Carbonic Anhydrase I Proteins 0.000 description 1
108010027522 Carbonic Anhydrase III Proteins 0.000 description 1
102100025518 Carbonic anhydrase 1 Human genes 0.000 description 1
102100024650 Carbonic anhydrase 3 Human genes 0.000 description 1
206010007733 Catabolic state Diseases 0.000 description 1
208000015879 Cerebellar disease Diseases 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
101710184994 Complement control protein Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
206010010301 Confusion and disorientation Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
229910001436 Cr3+ Inorganic materials 0.000 description 1
208000019736 Cranial nerve disease Diseases 0.000 description 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
108010065556 Drug Receptors Proteins 0.000 description 1
102000013138 Drug Receptors Human genes 0.000 description 1
241001269524 Dura Species 0.000 description 1
229910052692 Dysprosium Inorganic materials 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
229910052691 Erbium Inorganic materials 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108090000270 Ficain Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
102100040510 Galectin-3-binding protein Human genes 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
208000002927 Hamartoma Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000405147 Hermes Species 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
229910052689 Holmium Inorganic materials 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
101100138657 Homo sapiens PTN gene Proteins 0.000 description 1
101000881168 Homo sapiens SPARC Proteins 0.000 description 1
101100518500 Homo sapiens SPP1 gene Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
206010022773 Intracranial pressure increased Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001090 Lectins Chemical group 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
102000004318 Matrilysin Human genes 0.000 description 1
108090000855 Matrilysin Proteins 0.000 description 1
208000027007 Meningioma benign Diseases 0.000 description 1
206010027193 Meningioma malignant Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102100030335 Midkine Human genes 0.000 description 1
108010092801 Midkine Proteins 0.000 description 1
206010027951 Mood swings Diseases 0.000 description 1
208000034702 Multiple pregnancies Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
235000009421 Myristica fragrans Nutrition 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108010047771 Neuron-Glia Cell Adhesion Molecules Proteins 0.000 description 1
102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
108020003217 Nuclear RNA Proteins 0.000 description 1
102000043141 Nuclear RNA Human genes 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108010077077 Osteonectin Proteins 0.000 description 1
102000009890 Osteonectin Human genes 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000282579 Pan Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
102400000980 Pituitary adenylate cyclase-activating polypeptide 27 Human genes 0.000 description 1
102400000979 Pituitary adenylate cyclase-activating polypeptide 38 Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010035004 Prephenate Dehydrogenase Proteins 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108010079723 Shiga Toxin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101001060868 Strawberry mild yellow edge-associated virus Helicase Proteins 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
102000003698 Syndecan-3 Human genes 0.000 description 1
108090000068 Syndecan-3 Proteins 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
102100028644 Tenascin-R Human genes 0.000 description 1
229910052771 Terbium Inorganic materials 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000036826 VIIth nerve paralysis Diseases 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
108010006886 Vitrogen Proteins 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000002579 Wernicke Aphasia Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000009056 active transport Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000013938 anaplastic oligoastrocytoma Diseases 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
150000008064 anhydrides Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940124691 antibody therapeutics Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
201000009467 benign meningioma Diseases 0.000 description 1
206010004406 benign neoplasm of spinal cord Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000009766 cell sprouting Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
201000009498 cerebellopontine angle tumor Diseases 0.000 description 1
208000030239 cerebral astrocytoma Diseases 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical class CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
238000007428 craniotomy Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000012136 culture method Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
208000012106 cystic neoplasm Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000009274 differential gene expression Effects 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000005264 electron capture Effects 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
230000008451 emotion Effects 0.000 description 1
238000004836 empirical method Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000009764 endothelial cell sprouting Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
108060002894 fibrillar collagen Proteins 0.000 description 1
102000013373 fibrillar collagen Human genes 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
235000019836 ficin Nutrition 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000003682 fluorination reaction Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
238000012226 gene silencing method Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
230000037442 genomic alteration Effects 0.000 description 1
238000009650 gentamicin protection assay Methods 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
208000030316 grade III meningioma Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
102000045436 human SPARC Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
210000003168 insulating cell Anatomy 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035990 intercellular signaling Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
239000002523 lectin Chemical group 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
102000019758 lipid binding proteins Human genes 0.000 description 1
108091016323 lipid binding proteins Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000013173 literature analysis Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
239000001115 mace Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
208000030883 malignant astrocytoma Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
201000004058 mixed glioma Diseases 0.000 description 1
230000037230 mobility Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000009562 momordin Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
208000018429 neoplasm of parietal lobe Diseases 0.000 description 1
208000018411 neoplasm of temporal lobe Diseases 0.000 description 1
210000001020 neural plate Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
201000004598 occipital lobe neoplasm Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
206010073131 oligoastrocytoma Diseases 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940055729 papain Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
108700028325 pokeweed antiviral Proteins 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
108010094020 polyglycine Proteins 0.000 description 1
229920000232 polyglycine polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000018883 protein targeting Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
208000026759 receptive aphasia Diseases 0.000 description 1
229940051173 recombinant immunotoxin Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
231100000916 relative toxicity Toxicity 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
229940061353 temodar Drugs 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
108010020387 tenascin R Proteins 0.000 description 1
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
229950002376 tirapazamine Drugs 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000031998 transcytosis Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000001720 vestibular Effects 0.000 description 1
210000000752 vestibulocochlear nerve Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
239000012463 white pigment Substances 0.000 description 1